Form 4: Entrada Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold 600 shares of common stock at $18 per share on October 16, 2024, under a pre-arranged trading plan.

Summary

• Natarajan Sethuraman, the President of Research & Development at Entrada Therapeutics, sold 600 shares of the company's common stock on October 16, 2024.
• The sale was executed at a price of $18 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted by Sethuraman on December 14, 2023.
• Following the transaction, Sethuraman directly owns 183,216 shares of Entrada Therapeutics.
• The Form 4 filing was signed by Jared Cohen, as Attorney-in-Fact, on October 18, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates